Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction

被引:35
作者
Emberton, M. [1 ]
机构
[1] UCLH UCL, Comprehens Biomed Ctr, Univ Coll Hosp, London NW1 2BU, England
关键词
URINARY-TRACT SYMPTOMS; 5-ALPHA-REDUCTASE INHIBITOR DUTASTERIDE; QUALITY-OF-LIFE; COMBINATION THERAPY; CLINICAL PROGRESSION; SEXUAL DYSFUNCTION; MEN; TAMSULOSIN; EFFICACY; PERCEPTIONS;
D O I
10.1111/j.1742-1241.2010.02463.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Practice guidelines acknowledge the importance of patient preferences in determining the appropriate treatment of benign prostatic hyperplasia (BPH). Recent literature suggests that patient and physician perspectives and satisfaction with BPH treatment management may differ; this may have an impact on clinical outcomes and patient compliance. This review evaluates patients' and physicians' preferred treatment options for managing BPH and patient satisfaction with therapy. A Medline-based systematic review using the terms 'Benign prostatic hyperplasia' + 'Patient preference/perception/satisfaction' or 'Physician/urologist preference/perception' was performed. Patients prefer therapies affecting long-term disease progression over those that provide short-term symptom improvement, which contrasts with the beliefs of their physicians. The prescribing behaviour of urologists and primary care physicians can be very varied. Studies of patient satisfaction with specific treatments generally show a high level of overall satisfaction, but cross-study comparisons are limited because of heterogeneity in study design. The evidence to date suggests that patients' views and beliefs and those of their physician may not always be in agreement. Improved physician-patient communication will help determine the best treatment option for patients with BPH and may ensure greater compliance and treatment success.
引用
收藏
页码:1425 / 1435
页数:11
相关论文
共 31 条
[1]  
[Anonymous], GUID MAN BEN PROST H
[2]   Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride [J].
Barkin, J ;
Guimaraes, M ;
Jacobi, G ;
Pushkar, D ;
Taylor, S ;
van Vierssen Trip, OB .
EUROPEAN UROLOGY, 2003, 44 (04) :461-466
[3]   Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial [J].
Barkin, Jack ;
Roehrborn, Claus G. ;
Siami, Paul ;
Haillot, Olivier ;
Morrill, Betsy ;
Black, Libby ;
Montorsi, Francesco .
BJU INTERNATIONAL, 2009, 103 (07) :919-926
[4]   The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms [J].
Black, Libby ;
Grove, Alyson ;
Morrill, Betsy .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2009, 7
[5]   5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery [J].
Boyle, P ;
Roehrborn, C ;
Harkaway, R ;
Logie, J ;
de la Rosette, J ;
Emberton, M .
EUROPEAN UROLOGY, 2004, 45 (05) :620-627
[6]   Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms [J].
Cam, K ;
Akman, Y ;
Kayikci, A ;
Senel, F ;
Erol, A .
INTERNATIONAL JOURNAL OF UROLOGY, 2003, 10 (11) :582-586
[7]   Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia [J].
Debruyne, F ;
Barkin, J ;
van Erps, P ;
Reis, M ;
Tammela, TLJ ;
Roehrborn, C .
EUROPEAN UROLOGY, 2004, 46 (04) :488-495
[8]   Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort in clinical practice [J].
Desgrandchamps, Francois ;
Droupy, Stephane ;
Irani, Jacques ;
Saussine, Christian ;
Ccmenducci, Andrea .
BJU INTERNATIONAL, 2006, 98 (01) :83-88
[9]   Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey [J].
Emberton, M. ;
Marberger, M. ;
de la Rosette, J. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (01) :18-26
[10]   Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily [J].
Emberton, M ;
Elhilali, M ;
Matzkin, H ;
Harving, N ;
van Moorselaar, J ;
Hartung, R ;
Alcaraz, A ;
Vallancien, G .
UROLOGY, 2005, 66 (02) :316-322